Analysts Expect Modest 2012 Contribution from HPV Assay for Gen-Probe | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment analysts have weighed in on the US Food and Drug Administration's clearance of Gen-Probe's Aptima HPV assay, saying that they expect a modest revenue contribution in 2012 but a potentially significant ramp in sales over the following two years.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.